05/24/2021 | Press release | Archived content
According to Garry Honey, we find ourselves looking at the most complicated engine ever devised. Around the world, Lundbeck is respected for confronting the challenge of working with extremely complicated diseases like schizophrenia and other brain disorders.
Although we haven't been able to identify a biomarker or a set of biomarkers for schizophrenia yet, there is no reason to believe, that we won't find biomarkers for schizophrenia and other psychiatric diseases within the next ten years.
'I believe that this will happen, due to the convergence of several developments. We have made enormous strides in understanding brain function and have incredible tools at our disposal that are now maturing and generating new, meaningful insights,' says Garry Honey.
Garry Honey confidently believes, that the technical progression combined with three significant developments will pave the way for innovation within biomarkers in schizophrenia and other brain diseases:
This potent combination, of large amounts of data, from connected, continuous, intelligent devices, with the analytical tools to leverage it, is opening a huge potential in our understanding of the brain, and the problems that occur when misfiring brain regions result in devastating illnesses like schizophrenia.